Search
01/01/2023
Properties and cellular uptake of photo-triggered mixed metallosurfactant vesicles intended for controlled CO delivery in gas therapy
Trallero J., Camacho M., Marín-García M., Álvarez-Marimon E., Benseny-Cases N., Barnadas-Rodríguez R.. Properties and cellular uptake of photo-triggered mixed metallosurfactant vesicles intended for controlled CO delivery in gas therapy. COLLOIDS AND SURFACES B-BIOINTERFACES. 2023; 228DOI:10.1016/j.colsurfb.2023.113422. PMID:37356136. IF:5.400(Q1/2D).
01/01/2023
Author Correction: Elevated plasma complement factor H related 5 protein is associated with venous thromboembolism (Nature Communications, (2023), 14, 1, (3280), 10.1038/s41467-023-38383-y)
Iglesias M.J., Sanchez-Rivera L., Ibrahim-Kosta M., Naudin C., Munsch G., Goumidi L., Farm M., Smith P.M., Thibord F., Kral-Pointner J.B., Hong M.-G., Suchon P., Germain M., Schrottmaier W., Dusart P., Boland A., Kotol D., Edfors F., Koprulu M., Pietzner M., Langenberg C., Damrauer S.M., Johnson A.D., Klarin D.M., Smith N.L., Smadja D.M., Holmström M., Magnusson M., Silveira A., Uhlén M., Renné T., Martinez-Perez A., Emmerich J., Deleuze J.-F., Antovic J., Soria Fernandez J.M., Assinger A., Schwenk J.M., Souto Andres J.C., Morange P.-E., Butler L.M., Trégouët D.-A., Odeberg J.. Author Correction: Elevated plasma complement factor H related 5 protein is associated with venous thromboembolism (Nature Communications, (2023), 14, 1, (3280), 10.1038/s41467-023-38383-y). Nature Communications. 2023; 14(1)DOI:10.1038/s41467-023-43764-4. PMID:. IF:(Q/D).
01/01/2023
Resolvin D2 Attenuates Cardiovascular Damage in Angiotensin II-Induced Hypertension
del Campo, LSD, García-Redondo A.B., Rodríguez C., Zaragoza C., Duro-Sánchez S., Palmas F., De Benito-Bueno A., Socuéllamos P.G., Peraza D.A., Rodrigues-Díez R., Valenzuela C., Dalli J., Salaices M., Briones A.M.. Resolvin D2 Attenuates Cardiovascular Damage in Angiotensin II-Induced Hypertension. HYPERTENSION. 2023; 80(1)DOI:10.1161/HYPERTENSIONAHA.122.19448. PMID:36337053. IF:7.200(Q1/1D).
01/01/2023
Formación del dietista-nutricionista clínico en Latinoamérica: un espejo donde debe mirarse España
Nava-Gonzalez E.J., Apolinar-Jiménez E., Bénitez-Brito N., Pérez-Armijo P., Pérez-López A., Troncoso-Pantoj C., Bonilla D.A., Fernández-Villa T., Petermann-Rocha F., Gamero A., Pérez-Esteve É., Navarrete-Muñoz E.M., Lozano-Lorca M., Almendra-Pegueros R.. Formación del dietista-nutricionista clínico en Latinoamérica: un espejo donde debe mirarse España. Revista Espanola De Nutricion Humana Y Dietetica. 2023; 27(2)DOI:10.14306/renhyd.27.2.1957. PMID:. IF:(Q/D).
01/01/2023
Desafíos alimentarios para un mundo que envejece
Petermann-Rocha F., Troncoso-Pantoja C., Gamero A., Pérez-Armijo P., Carrillo-Alvarez E., Daga R., Reig García-Galbis M., Pérez-López A., Benítez Brito N., Fernández-Villa T., Bonilla D.A., Lozano-Lorca M., Kouiti M., Kammar-García A., Nava-González E.J., Almendra-Pegueros R.. Desafíos alimentarios para un mundo que envejece. Revista Espanola De Nutricion Humana Y Dietetica. 2023; 27(3)DOI:10.14306/renhyd.27.3.1975. PMID:. IF:(Q/D).
01/01/2023
¿Cuál es el papel de las y los editores en la comunicación y difusión científica? Análisis desde el equipo editorial de la Revista Española de Nutrición Humana y Dietética
Troncoso-Pantoja C., Petermann-Rocha F., Pérez-Armijo P., Gamero A., Carrillo-Alvarez E., Apolinar-Jiménez E., García-Galbis M.R., Pérez-Esteve É., Daga R., Lozano-Lorca M., Nava-González E.J., Bonilla D.A., Kouiti M., Almendra-Pegueros R.. ¿Cuál es el papel de las y los editores en la comunicación y difusión científica? Análisis desde el equipo editorial de la Revista Española de Nutrición Humana y Dietética. Revista Espanola De Nutricion Humana Y Dietetica. 2023; 27(3)DOI:10.14306/renhyd.27.3.1998. PMID:. IF:(Q/D).
01/01/2023
An spanish study of secondary findings in families affected with mendelian disorders: choices, prevalence and family history
Codina-Sola, M, Trujillano, L, Abuli, A, Rovira-Moreno, E, Munoz-Cabello, P, Campos, B, Fernandez-Alvarez, P, Palau, D, Carrasco, E, Valenzuela, I, Cueto-Gonzalez, AM, Lasa-Aranzasti, A, Limeres, J, Leno-Colorado, J, Costa-Roger, M, Moles-Fernandez, A, Balmana, J, Diez, O, Cusco, I, Garcia-Arumi, E, Tizzano, EF. An spanish study of secondary findings in families affected with mendelian disorders: choices, prevalence and family history. EUROPEAN JOURNAL OF HUMAN GENETICS. 2023; 31(2)DOI:10.1038/s41431-022-01240-5. PMID:36446894. IF:3.700(Q2/3D).
01/01/2023
An European overview of genetic counselling supervision provision
Paneque M., Guimarães L., Bengoa J., Pasalodos S., Cordier C., Esteban I., Lemos C., Moldovan R., Serra-Juhé C.. An European overview of genetic counselling supervision provision. European Journal of Medical Genetics. 2023; 66(4)DOI:10.1016/j.ejmg.2023.104710. PMID:36731744. IF:1.600(Q4/8D).
01/01/2023
A novel phenotype of AChR-deficiency syndrome with predominant facial and distal weakness resulting from the inclusion of an evolutionary alternatively-spliced exon in CHRNA1
Rodríguez Cruz P.M., Ravenscroft G., Natera D., Carr A., Manzur A., Liu W.W., Vella N.R., Jericó I., Gonzalez-Quereda L., Gallano P., Montalto S.A., Davis M.R., Lamont P.J., Laing N.G., Bourque P., Nascimento A., Muntoni F., Polavarapu K., Lochmüller H., Palace J., Beeson D.. A novel phenotype of AChR-deficiency syndrome with predominant facial and distal weakness resulting from the inclusion of an evolutionary alternatively-spliced exon in CHRNA1. NEUROMUSCULAR DISORDERS. 2023; 33(2)DOI:10.1016/j.nmd.2022.12.011. PMID:36634413. IF:2.700(Q2/4D).
01/01/2023
Remnant cholesterol: new outcomes highlight its potential as a clinically useful cardiovascular risk factor
Ferrer R., Mansilla A., Tondo M., Blanco-Vaca F.. Remnant cholesterol: new outcomes highlight its potential as a clinically useful cardiovascular risk factor. Journal Of Laboratory And Precision Medicine. 2023; 8DOI:10.21037/jlpm-22-70. PMID:. IF:(Q/D).
01/01/2023
All-cause and cardiorenal mortality in 6 million adults with and without type 2 diabetes: A comparative, trend analysis in Canada, Spain, and the UK
Ling S., Zaccardi F., Vlacho B., Li P., Gatius, JR, Mata-Cases M., Franch-Nadal J., Kosiborod M.N., Gillies C., Fenici P., Mauricio D., Shah B.R., Khunti K.. All-cause and cardiorenal mortality in 6 million adults with and without type 2 diabetes: A comparative, trend analysis in Canada, Spain, and the UK. DIABETES OBESITY & METABOLISM. 2023; 25(1)DOI:10.1111/dom.14856. PMID:36056765. IF:5.400(Q1/2D).
01/01/2023
Type 2 Diabetes mellitus alters the cargo of (poly)phenol metabolome and the oxidative status in circulating lipoproteins
Reis A., Rocha S., Dias I.H., Costa R., Soares R., Sánchez-Quesada J.L., Perez A., de Freitas V.. Type 2 Diabetes mellitus alters the cargo of (poly)phenol metabolome and the oxidative status in circulating lipoproteins. Redox Biology. 2023; 59DOI:10.1016/j.redox.2022.102572. PMID:36516720. IF:10.700(Q1/1D).
01/01/2023
Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database
Muller-Wieland, D, Freemantle, N, Bonadonna, RC, Mauquoi, C, Bigot, G, Bonnemaire, M, Gourdy, P, Mauricio, D. Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database. Diabetes Therapy. 2023; 14(2)DOI:10.1007/s13300-022-01356-3. PMID:36596946. IF:2.800(Q3/6D).
01/01/2023
Is There a Link between Obesity Indices and Skin Autofluorescence? A Response from the ILERVAS Project
Sánchez E., Sánchez M., López-Cano C., Bermúdez-López M., Valdivielso J.M., Farras-Salles, C, Pamplona R., Torres G., Mauricio D., Castro E., Fernández E., Lecube A.. Is There a Link between Obesity Indices and Skin Autofluorescence? A Response from the ILERVAS Project. Nutrients. 2023; 15(1)DOI:10.3390/nu15010203. PMID:36615860. IF:4.800(Q1/2D).
01/01/2023
Obesity and fertility. Position statement
Miñambres I., de Hollanda A., Vilarrasa N., Pellitero S., Rubio M.A., Flores L., Caixàs A., Lobo S., Martinez Salamanca J.I., Acevedo B., Moizé V., Andreu A., Escalada J.. Obesity and fertility. Position statement. Endocrinologia Diabetes y Nutricion. 2023; 70DOI:10.1016/j.endinu.2022.10.002. PMID:. IF:(Q/D).
01/01/2023
Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología
Pedro-Botet J., Barrios V., Sánchez-Margalet V., Tamargo J., Arrieta F., Gámez J.M., Gimeno-Orna J.A., Escobar C., Gómez-Doblas J.J., Pérez A.. Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología. Endocrinologia Diabetes y Nutricion. 2023; 70DOI:10.1016/j.endinu.2022.03.004. PMID:. IF:(Q/D).
01/01/2023
Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open-label, multinational, randomised, controlled, non-inferiority trial
Mathiesen E.R., Alibegovic A.C., Corcoy R., Dunne F., Feig D.S., Hod M., Jia T., Kalyanam B., Kar S., Kautzky-Willer A., Marchesini C., Rea R.D., Damm P.. Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open-label, multinational, randomised, controlled, non-inferiority trial. Lancet Diabetes & Endocrinology. 2023; 11(2)DOI:10.1016/S2213-8587(22)00307-2. PMID:36623517. IF:44.000(Q1/1D).
01/01/2023
Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study
Julián M.T., Ballesta S., Pera G., Pérez-Montes de Oca A., Soldevila B., Caballería L., Morillas R., Expósito C., Martínez–Escudé A., Puig-Domingo M., Franch-Nadal J., Torán P., Cusi K., Julve J., Mauricio D., Alonso N.. Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study. Frontiers in Endocrinology. 2023; 13DOI:10.3389/fendo.2022.1051958. PMID:36714592. IF:3.900(Q2/3D).
01/01/2023
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino T., Alexander C.M., Amiel S.A., Arreaza-Rubin G., Beck R.W., Bergenstal R.M., Buckingham B.A., Carroll J., Ceriello A., Chow E., Choudhary P., Close K., Danne T., Dutta S., Gabbay R., Garg S., Heverly J., Hirsch I.B., Kader T., Kenney J., Kovatchev B., Laffel L., Maahs D., Mathieu C., Mauricio D., Nimri R., Nishimura R., Scharf M., Del Prato S., Renard E., Rosenstock J., Saboo B., Ueki K., Umpierrez G.E., Weinzimer S.A., Phillip M.. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes & Endocrinology. 2023; 11(1)DOI:10.1016/S2213-8587(22)00319-9. PMID:36493795. IF:44.000(Q1/1D).
01/01/2023
Spanish Consensus on the Use of isCGM in the Management of Patients With Insulin Therapy: The MONITOR Project
Ampudia-Blasco F.J., Ugarte-Abasolo E., Chico A., García-Alemán J., Galan-Barroso M.. Spanish Consensus on the Use of isCGM in the Management of Patients With Insulin Therapy: The MONITOR Project. Journal Of Diabetes Science And Technology. 2023; 17(5)DOI:10.1177/19322968221087270. PMID:35466722. IF:(Q/D).